Natalie Grover, MD

62 posts

Natalie Grover, MD banner
Natalie Grover, MD

Natalie Grover, MD

@NatalieGroverMD

Associate Professor at UNC School of Medicine. Lymphoma and CAR-T physician and clinical researcher. Opinions are my own.

Chapel Hill, NC Katılım Haziran 2021
294 Takip Edilen187 Takipçiler
Natalie Grover, MD retweetledi
Katharine Lewis
Katharine Lewis@Dr_KatLewis·
Delighted to share our work now published on behalf of all co-authors. Our practice has changed- minimal use of HD-MTX in CNS prophylaxis in aNHL. Thank you so much to all international collaborators! ascopubs.org/doi/10.1200/JC…
English
7
31
108
14.5K
Natalie Grover, MD retweetledi
Daniel Pollyea
Daniel Pollyea@DanPollyea·
⁦@LeukDocJZ⁩ speaking at the first annual Thomas Shea clinical cancer symposium on immune modulation in#AML. Great meeting in honor of a great leader and mentor in the field. ⁦@UNC_Lineberger⁩
Daniel Pollyea tweet media
English
0
2
15
1.3K
Natalie Grover, MD retweetledi
Joshua Zeidner MD
Joshua Zeidner MD@LeukDocJZ·
Amazing way to close #SheaSymposium with @sairah__ahmed giving an excellent roadmap and overview of the current treatment armamentarium and future directions of CAR T cell therapy in lymphoma 👏👏👏@UNC_Lineberger
Joshua Zeidner MD tweet media
English
0
1
5
740
Natalie Grover, MD retweetledi
Nick Tschernia, MD
Nick Tschernia, MD@NickTscherniaMD·
Happy to share PROs & Cons of CD30 CAR T cell tx in heavily pre-tx'd pts w/ R/R CD30+ lymphomas. Tx was overall well tolerated w/ patient reported outcomes showing recovery to at least their baseline 1mo post-tx. Thx to patients, @NatalieGroverMD, @SeroBMT1, & @UNC_Lineberger!
Journal for ImmunoTherapy of Cancer@jitcancer

Let’s take a closer look at recent #JITC publication: “Patient Reported Outcomes in CD30 Directed CAR-T Cells against relapsed/refractory CD30+ lymphomas” jitc.bmj.com/content/11/8/e… 1/3

English
0
2
10
1.2K
Natalie Grover, MD retweetledi
Eddie Cliff
Eddie Cliff@Eddie_Cliff·
Fantastic job @gloria_iacoboni in the great debate, CAR T vs bispecifics for DLBCL: “Would you rather a bright red CAR or a bike-specific antibody?” #17ICML
Eddie Cliff tweet media
English
3
10
56
7.1K
Natalie Grover, MD retweetledi
Daniel Molin
Daniel Molin@Dr_Daniel_Molin·
Shadman. Convincingly arguing for “functional cure” in FL treated with chemo immunotherapy. 15 y OS 70% PFS 40%. Average rate of progression decreased over time. #17ICML
Daniel Molin tweet media
English
0
5
10
1.8K
Natalie Grover, MD retweetledi
Alexandra Rojek
Alexandra Rojek@AlexandraRojek·
Long term (7yr) follow up of LYMA trial - @LysaLymphoma rituximab maintenance study after autoSCT in MCL by @clementinesar - continued PFS benefit, no OS difference, and no increase of relapse after R discontinuation, but continued unmet need in POD24 population #ICML23 #17ICML
Alexandra Rojek tweet mediaAlexandra Rojek tweet mediaAlexandra Rojek tweet mediaAlexandra Rojek tweet media
Lugano, Switzerland 🇨🇭 English
1
5
13
1.1K
Natalie Grover, MD retweetledi
Eddie Cliff
Eddie Cliff@Eddie_Cliff·
Pity to see this Burkitt lymphoma study close early - means we will likely never have a definitive answer to this question (As highlighted by Prof Seymour @Haem_pmcc_rmh) A reminder of the challenges of running a trial on a highly aggressive rare disease #17ICML
Ajay Major, MD, MBA@majorajay

RCT of EPOCH v Magrath in high-risk Burkitt #17ICML - 89 pts (closed early, planned 250 pts) - 92% got all CODOX/IVAC cycles - 2-yr PFS no difference between arms, OS 75% both arms - no CNS relapses, more infx AEs in CODOX Valiant effort, not sure if changes practice. #lymsm

Paradiso, Svizzera 🇨🇭 English
1
4
14
2.3K

Keşfet

@TheCTSU @SWOG @ALLIANCE_org @eaonc @NRGonc @sairah_ahmed @ASH_Hematology @AFMDA